Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lorlatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 21,746Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer and Strata expand clinical partnership for cancer trial
    Pfizer and Strata expand clinical partnership for cancer trial

    14 Sep 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/pfizer-strata-partnership-cancer-trial/

    CLINICALTRIALSARENA
    14 Sep 2022
    Share Share
    Amber Specialty Added to Pfizer’s Limited Distribution Network
    Amber Specialty Added to Pfizer’s Limited Distribution Network

    03 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220803005649/en

    BUSINESSWIRE
    03 Aug 2022
    Share Share
    Pfizer’s Lorviqua OKed as 1st-line therapy for ALK-positive NSCLC
    Pfizer’s Lorviqua OKed as 1st-line therapy for ALK-positive NSCLC

    19 May 2022

    // Kim Yun-mi KOREABIOMED

    http://www.koreabiomed.com/news/articleView.html?idxno=13724

    Kim Yun-mi KOREABIOMED
    19 May 2022
    Share Share
    EC Approves LORVIQUA as First-Line Treatment for ALK-Positive NSCLC
    EC Approves LORVIQUA as First-Line Treatment for ALK-Positive NSCLC

    28 Jan 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220128005304/en

    BUSINESSWIRE
    28 Jan 2022
    Share Share
    Pfizer’s Lorbrena gets US FDA approval to treat ALK-positive nsclc
    Pfizer’s Lorbrena gets US FDA approval to treat ALK-positive nsclc

    04 Mar 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=135923&sid=2

    PHARMABIZ
    04 Mar 2021
    Share Share
    Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval
    Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval

    04 Mar 2021

    // Lucy Parsons PMLIVE

    http://www.pmlive.com/pharma_news/pfizers_alk_inhibitor_lorbrena_scores_expanded_fda_approval_for_first-line_nsclc_1364615

    Lucy Parsons PMLIVE
    04 Mar 2021
    Share Share